Table 2. Clinically applicable multigene signature.
| Signature [year] | Tumor histology | Number of genes in signature | Risk groups | Prognostic | Predictive for ACT | Training set | Test sets | HR in testing set | HR for high risk | FFPE ready |
|---|---|---|---|---|---|---|---|---|---|---|
| Zhu [2010] (32) | NSCLC | 15 | Median dichotomized | Yes | Yes | BR10 | DCC | 1.96-3.57 | 0.54 | No |
| Duke | ||||||||||
| UM-SQ | ||||||||||
| NLCI | ||||||||||
| Kratz [2012] (34) | Non-Squamous NSCLC | 14 | Tertile | Yes | NT | UCSF | KPDOR | 1.60-2.37 | NA | Yes |
| CCTC | ||||||||||
| Van Laar [2012] (35) | NSCLC | 160 | < or >60% | Yes | NT | DCC | BR10 | 2.02-2.23 | NA | No |
| Harvard | ||||||||||
| Duke | ||||||||||
| Nagoya_A | ||||||||||
| NSCLC | 37 | < or >60% | No | Yes | DCC | BR10 | NA | 0.23 | No | |
| Chen [2011] (36) | NSCLC | 94 | Median dichotomized | Yes | Yes | MSKCC | DCC | 2.10-2.57 | 0.48 | No |
| BR10 | ||||||||||
| Nagoya_B | ||||||||||
| Tang [2013] (37) | Non-Squamous NSCLC | 12 | Median dichotomized | Yes | Yes | DCC | UTSW | 1.55-3.19 | 0.36 | No |
| Nagoya_A Nagoya_B | ||||||||||
| Samsung | ||||||||||
| Duke | ||||||||||
| UM-SQ BR10 | ||||||||||
| Wistuba [2013] (38) | ADC | 31 | Median dichotomized | Yes | NT | 96 prostate | DCC | 1.95 | NA | Yes |
| NCCHJ | ||||||||||
| Cancer samples | MDACC | |||||||||
| &IEO |
BR10, NCIC Clinical Trials BR.10 (GSE14814); DCC, Directors’ Challenge Consortium (data at https://array.nci.nih.gov/caarray/project/jacob-00182); Duke, Duke University (GSE3141), UM-SQ, University of Michigan squamous cell carcinoma (GSE4573); NLCI, Netherlands Cancer Institute (data at http://research.agendia.com/); UCSF, University of California, San Francisco; KPDOR, Kaiser Permanente Division of Research; CCTC, China Clinical Trials Consortium; Harvard, Harvard University (data at http://www.broadinstitute.org/mpr/lung/); Nagoya_A, Nagoya University (GSE11969); Nagoya_B, Nagoya University (GSE13213); Samsung, Samsung Medical Centre (GSE8894); MSKCC, Memorial Sloan Kettering Cancer Centre (GSE10780); UTSW, University of Texas South Western (GSE42127); NCCHJ, National Cancer Center Hospital of Japan (GSE31210); MDACC, MD Aderson cancer Center; IEO, European Institute of Oncology; HR, Hazard Ratio.